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Amikacin use and Therapeutic Drug Monitoring in adults: Do 1 
dose regimens and drug exposures affect either outcome or 2 
adverse events? 3 
 4 
BSAC Working Party on Therapeutic Drug Monitoring¥. 5 
 6 
7 
  
Abstract 8 
Objectives 9 
To identify the amikacin dosage regimens and drug concentrations 10 
consistent with good outcomes and to determine the drug 11 
exposures related to nephrotoxicity and ototoxicity. 12 
Methods 13 
A literature review was conducted in Medline, EMBASE and the 14 
Cochrane Central Register of Controlled Trials. Full journal articles of 15 
randomised controlled trials, controlled clinical trials, interrupted 16 
time series trials and controlled before and after studies involving 17 
amikacin TDM and dose adjustment were considered for inclusion. 18 
Results 19 
Seventeen included studies were identified, comprising 1677 20 
participants. Amikacin doses ranged from 11-15 mg/kg/day with 21 
thirteen studies using 15 mg/kg/day. Studies were generally 22 
designed to compare different aminoglycosides rather than to 23 
assess concentration-effect relationships. Only eleven papers 24 
presented data on target concentrations, rate of clinical cure and 25 
toxicity.  Target peak concentrations ranged from 15  W 40 mg/L and 26 
target troughs were typically <10 mg/L or <5 mg/L.  It was not clear 27 
whether these targets were achieved. Measured peaks averaged 28 28 
mg/L for twice daily dosing and 40-45 mg/L for once daily dosing; 29 
troughs averaged 5 mg/L and 1-2 mg/L, respectively.  30 
Fifteen of the included studies reported rates of nephrotoxicity; 31 
auditory and vestibular toxicities were reported in twelve and eight 32 
studies.  33 
  
 34 
Conclusions 35 
This systematic review found little published evidence to support an 36 
optimal dosage regimen or TDM targets for amikacin therapy.   37 
The use of alternative approaches, such as consensus opinion and a 38 
review of current practice, will be required to develop guidelines to 39 
maximise therapeutic outcomes and minimise toxicity with 40 
amikacin. 41 
 42 
Background   43 
Five aminoglycosides are listed in the British National Formulary for 44 
clinical use in the UK: amikacin, gentamicin, neomycin (only topical), 45 
streptomycin (mainly for tuberculosis) and tobramycin.1  All 46 
systemically administered aminoglycosides have a narrow 47 
therapeutic window and there is wide variability in the relationship 48 
between the dose and the measured serum level. Not all of this 49 
variability can be explained by clinical factors, such as renal function 50 
and the physiological changes that occur in sepsis. Consequently, 51 
over the last forty years therapeutic drug monitoring (TDM) has 52 
been an integral part of the management of patients during 53 
treatment with an aminoglycoside. TDM has helped to reduce the 54 
incidence of adverse events seen with this class of antibacterial, and 55 
in the UK most patients receiving more than a few days of therapy 56 
with such agents will have their serum level monitored by TDM. 57 
 58 
  
Although historically there has been a consensus on the general 59 
objectives of TDM for aminoglycosides, at present there are almost 60 
no evidence-based guidelines, and in a number of areas there is 61 
wide international variation and controversy. Since the mid-1990s, 62 
there has been a general trend towards the use of once-daily 63 
administration (extended dosing interval) for aminoglycosides and 64 
much of the usage in the UK is on this basis.  65 
 66 
One of the frequently monitored aminoglycosides for which there is 67 
a pressing need for clear guidance is amikacin. From an extensive 68 
search, there is only one systematic review which compares once-69 
daily dosing with multiple-daily dose administration.2  Due to a lack 70 
of high quality evidence to support dosage recommendations, 71 
locally developed guidelines are forced to select management 72 
pathways without a clear understanding of the optimal treatment 73 
and preferred TDM regimen. This review will cover the scientific 74 
basis for both the dosing and TDM of amikacin.  75 
 76 
Objectives   77 
To identify amikacin TDM regimens and drug concentrations 78 
consistent with good outcomes and to determine drug exposures 79 
related to the adverse events of nephrotoxicity and ototoxicity in 80 
adults. 81 
 82 
Methods   83 
  
This literature review considered TDM and dose adjustment for 84 
amikacin as a single agent. Comparators could be single or 85 
combination agents or different treatment durations or regimens. 86 
The inclusion criteria comprised adults with infections treated with 87 
amikacin and aged 18 and above, randomised control trials (RCT), 88 
controlled clinical trials (CCTs), interrupted time series with at least 89 
three data points before and after implementation of the guideline 90 
(ITS) and controlled before and after studies (CBA).  Full details of 91 
the protocol are presented in the Supplementary Data. 92 
 93 
Searches were conducted in Medline, EMBASE and the Cochrane 94 
Central Register of Controlled Trials (CENTRAL), published in The 95 
Cochrane Library.  Reference lists of included studies were scanned 96 
to identify any further studies that had not been identified by 97 
electronic searching. 98 
 99 
Studies meeting the inclusion criteria were identified by two authors 100 
(AJ, PW) independently and any discrepancies were resolved by 101 
discussion with other authors. Studies which were excluded after an 102 
initial sorting were recorded with a brief description of the reason 103 
for exclusion. Studies were restricted to those in the English 104 
language.  A data extraction form was developed to facilitate the 105 
collection of data from each of the included studies.  106 
 107 
Two authors independently assessed the risk of bias for each study 108 
and the Cochrane Risk of bias tool for randomised controlled trials 109 
  
was adapted for this review.3  Each study was assessed for selection, 110 
detection and attrition biases and also possible biases confounded 111 
by small size and sponsorship. Additional information can be found 112 
in the supplementary information to this article. 113 
 114 
Results   115 
The literature search was initially run in 2013 and updated in June 116 
2015 when no new included studies were identified.  A PRISMA flow 117 
chart is presented in Figure S1. Seventeen included studies (22 118 
reports) comprising 1677 participants were identified during the 119 
literature search which are summarised in table S1.  Four of these 120 
studies comprised more than one report:  121 
-
 Ibrahim et al (Ibrahim et al and two papers published by 122 
Tulkens et al).4,5,6 123 
-
 Maller et al (four papers published by Maller between 1988 124 
and 1993).7,8,9,10 125 
-
 Smith et al (three papers published by Smith between 1977 126 
and 1983).11,12,13 127 
- Gatell (three papers published by Gatell between 1983 and 128 
1987).14,15,16  129 
 130 
Two papers were non-evaluable.  The study by Kiel et al17, had a 131 
short follow-up time (1.3 days), high drop out rate (55%) and 132 
unclear study population. DeMaria et al 18 combined the results of 133 
the tobramycin and amikacin arms. Of the 15 evaluable studies, five 134 
compared different amikacin dosage regimens, nine compared 135 
  
amikacin with another aminoglycoside and one compared amikacin 136 
with cefotaxime (table 1). Galvez et al20 provided little data on cure 137 
or toxicity and was also excluded. Amikacin doses ranged from 9-15 138 
mg/kg/day; thirteen studies used 15 mg/kg/day.   139 
 140 
Effects of interventions   141 
Amikacin concentrations 142 
Eleven studies used TDM with dose modification to achieve 143 
concentrations within a pre-defined range but did not confirm if 144 
their targets were  achieved.2,7,11,14,19,20,21,22,23,24,25,26  Dillon19 divided 145 
patients into two arms and modified doses in response to serum 146 
amikacin concentrations in one arm.  In three papers, serum 147 
concentrations were measured but no action was taken.4,27,28  148 
 149 
Clinical Cure 150 
As only one study8 compared clinical cure rates with different 151 
amikacin dosage regimens, there were insufficient data to conduct a 152 
meta-analysis.  Four papers compared clinical cure rates with 153 
amikacin and another aminoglycoside in bacteraemic 154 
patients.11,21,24,25 The meta-analysis included 479 participants and is 155 
presented in figure S2.  There was no difference in clinical cure rate 156 
between amikacin and other aminoglycosides (risk ratio 1.00, 95% CI 157 
0.90, 1.12). 158 
 159 
Nephrotoxicity 160 
  
Four of the 5 studies that compared amikacin dosage regimens were 161 
included in the meta-analysis; the remaining study20 reported  ?no 162 
evidence of renaůĨƵŶĐƚŝŽŶŝŵƉĂŝƌŵĞŶƚĂƚĚĂǇ ? ? ?.  Figure S3 shows 163 
a non-significant risk ratio of 1.42 (95% CI 0.68, 2.93) in favour of 164 
once daily administration. 165 
Data on nephrotoxicity rates were available from 9 studies (872 166 
patients) that compared amikacin to another aminoglycoside; one 167 
additional study28 found no evidence of nephrotoxicity.  The meta-168 
analysis presented in figure 1 shows a significant risk ratio of 0.48 169 
(95% CI 0.32, 0.72) in favour of amikacin over other 170 
aminoglycosides. 171 
 172 
Auditory Toxicity 173 
The results of three papers2,3,8 that compared auditory toxicity with 174 
different amikacin dosage regimens are summarised in figure S4. 175 
There was a non- significant risk ratio of 0.77 (95% CI 0.28, 2.11) in 176 
favour of twice daily amikacin. All nine papers that compared 177 
amikacin with another aminoglycoside included rates of auditory 178 
toxicity.  Figure 2 shows a non- significant risk ratio of 1.15 (95% CI 179 
0.76, 1.76) in favour of other aminoglycosides over amikacin. 180 
 181 
Vestibular Toxicity 182 
Maller et al7 is the only paper that evaluated vestibular toxicity with 183 
different amikacin dosage regimens.  The results from 4 studies that 184 
compared vestibular toxicity with amikacin and other 185 
aminoglycosides are summarised in figure S5.  There was a non- 186 
  
significant risk ratio of 1.61 (95% CI 0.39, 6.68) in favour of other 187 
aminoglycosides over amikacin. 188 
 189 
Secondary Outcomes 190 
Only Maller et al7,8,9,10 presented data on 28 day mortality and 191 
Dillon18 on length of hospital stay with different amikacin dosage 192 
regimens.  Two studies reported on duration of therapy.4,19 Only one 193 
paper reported 28-day mortality with amikacin and each of 194 
gentamicin11, tobramycin14 and netilmicin.24 One death was 195 
reported in the Barza et al23 study but it was not clear if this 196 
occurred with amikacin or netilmicin. None of the papers considered 197 
length of hospital stay as an outcome; five papers presented data on 198 
duration of therapy.   Only Bock et al24 described a patient who 199 
required an alternative antibiotic due to treatment failure with 200 
netilmicin. None of these papers presented data that related 201 
concentration measurements to cure or nephrotoxicity. 202 
 203 
An assessment of bias was completed for all included studies and 204 
shown in figure S6. 205 
 206 
Excluded Studies 207 
Twenty-eight studies were excluded and the reasons can be found in 208 
Table S2 in the supplementary information to this paper. 209 
 210 
Discussion 211 
  
In contrast to previously published reviews, which assessed the 212 
relative benefits of amikacin administered once or multiple times 213 
each day29,30,31,32, the present review used an evidence-based 214 
methodology to investigate dosing and TDM regimens associated 215 
with best patient outcomes. To this end little published evidence 216 
was found to support optimal dosage regimens or TDM targets for 217 
amikacin therapy.  Studies that met the inclusion criteria were 218 
typically designed to compare different aminoglycosides, rather 219 
than to examine the impact of dosing regimens and TDM on 220 
outcomes and toxicities. Even those studies which compared once 221 
and twice daily amikacin dosage regimens provided little 222 
information on the value of TDM.   223 
 224 
The review aimed to focus on proven Gram-negative bacteraemia, 225 
however, most studies included patients with a variety of infections 226 
and a mixture of suspected and proven bacteraemias. Clinical cure 227 
rates were generally high and amikacin was found to be at least 228 
equivalent to that of other aminoglycosides, depending on organism 229 
sensitivity. However, since aminoglycosides achieve high 230 
concentrations in the urine, caution is required when comparing 231 
data on the treatment of urinary tract infections with data on 232 
systemic infections, particularly in critically ill patients.  233 
 234 
Another clear finding was that amikacin is associated with 235 
nephrotoxicity and ototoxicity, particularly auditory toxicity. 236 
Interestingly, the reported incidence of auditory and vestibular 237 
  
toxicities was at least comparable to, if not higher than, the 238 
reported incidence of nephrotoxicity in many studies.  However, no 239 
conclusions can be drawn about the toxicity of amikacin relative to 240 
other aminoglycosides since that was outside the scope of this 241 
review and relevant data are therefore likely to be missing.  242 
Furthermore, there were wide variations in individual study 243 
characteristics regarding the definition of nephrotoxicity, 244 
assessment of ototoxicity, duration of therapy, concurrent 245 
medication, aminoglycoside concentrations and exposure.  These 246 
variabilities confounded the interpretation of both toxicity incidence 247 
rates and potential relationships between nephrotoxicity and 248 
amikacin concentrations or exposure. 249 
 250 
This review originally planned to examine patients >75 years old or 251 
with an estimated creatinine clearance <60 mL/min as a separate 252 
group.  However, none of the included studies characterised these 253 
patients separately and exclusion criteria varied widely, ranging 254 
from creatinine concentrations >180 micromol/L to patients 255 
receiving dialysis.  256 
 257 
Most studies did not include any commentary on dosing in patients 258 
with altered pharmacokinetics or body habitus. Only one study 259 
specified the use of lean body weight for dosing purposes.24 One 260 
study examined patients with liver cirrhosis, which is likely to have 261 
additional effects on drug handling.26 262 
 263 
  
As most of the included studies were published before once daily 264 
dosing of aminoglycosides became routine clinical practice, most 265 
target ranges related to doses of 7.5 mg/kg every 8-12 hours.  Peak 266 
concentrations ranged from 15  W 40 mg/L one hour after an IM 267 
injection or 20 to 30 minutes after a 20 or 30 minute IV infusion and 268 
most studies aimed for a trough of either <10 mg/L or <5 mg/L. One 269 
study aimed for a trough <30 mg/L.26 Although concentrations were 270 
measured using a range of different assay techniques, measured 271 
peak concentrations with twice daily dosing averaged around 28 272 
mg/L and troughs around 5 mg/L.  Target serum concentrations for 273 
once daily dosing were identified in two studies.2,7 Both aimed for 274 
trough concentrations of <5 mg/L, one also examined the incidence 275 
of peaks >40 mg/L.2  Measured peak and trough concentrations with 276 
once daily dosing averaged 40-45 mg/L and 1-2 mg/L, respectively. 277 
Although the review found insufficient evidence to compare once 278 
and multiple daily dosing, pharmacokinetic and pharmacodynamic 279 
principles support the current practice of extended interval dosing 280 
to achieve the high peak to MIC ratios that are now considered 281 
optimal.   282 
 283 
Although mean values reflected the proposed target ranges for once 284 
and twice daily dosage regimens, individual measured 285 
concentrations were very variable, ranging from 12 to 127 mg/L for 286 
peak concentrations and 1  W 74 mg/L for trough concentrations.  It is 287 
likely that this variability in reported concentrations reflected the 288 
use of fixed dose regimens in patients whose renal function covered 289 
  
a wide range.  Only one study reported dose adjustments for renal 290 
impairment,7 In contrast with current practice for gentamicin 291 
dosing, they modified the dose amount rather than the dosage 292 
interval. In this study, trough concentrations >5 mg/L were observed 293 
in seven of the nine patients on once daily dosing and nine of the 294 
eleven patients on twice daily dosing who had nephrotoxicity.7 295 
 296 
The present review has a number of limitations.  Only two of the 297 
seventeen included papers had more than 200 participants and the 298 
potential for bias was high.  Studies frequently did not describe how 299 
randomisation was achieved and were not double blind. Most of the 300 
included studies were published before 1995, do not reflect current 301 
practice and offered little opportunity to examine the impact of 302 
clinical factors, such as weight, renal function, severity of illness and 303 
Cmax/MIC ratio on clinical outcomes. An additional limitation is that 304 
aminoglycosides are normally used in combination with other 305 
antimicrobial agents, leading to a complex relationship between 306 
therapy and outcome.  Several recent studies on TDM were 307 
excluded from the present analysis because their methodology did 308 
not comply with the inclusion criteria. However, such studies may 309 
provide useful data to support opinion-based guidelines. For 310 
example, Duszynska et al33 provide data to suggest that higher doses 311 
and concentrations of amikacin may be required to manage patients 312 
with sepsis. 313 
 314 
Conclusions   315 
  
This systematic review has demonstrated that there are insufficient 316 
data to produce evidence-based guidelines for amikacin dosing and 317 
TDM. Future studies should clearly specify the clinical characteristics 318 
of participants, indications, dosage regimens, concentrations, 319 
Cmax/MIC ratios and outcomes in terms of clinical cure and relevant 320 
adverse effects.  Furthermore, traditional systematic review 321 
methodology should be expanded to examine outcomes based on 322 
PK/PD modelling techniques.  At present, guidelines to maximise 323 
therapeutic outcomes and minimise toxicity with amikacin must be 324 
based on reviews of current practice, published guidelines and 325 
expert opinion. 326 
 327 
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Table 1: Summary of Included Evaluable Papers  484 
Author No. 
Particip
ants 
Amikacin 
Regimen 
Comparator Clinical Cure Nephrotoxicity Auditory Toxicity Vestibular Toxicity 28 Day Mortality Duration of 
Therapy (days) 
Target or Measured Serum 
Concentrations (mg/L) 
   Drug  Regimen Ami Comp Ami Comp Ami Comp Ami Comp Ami Comp Ami Comp Ami Comp 
Dillon18 82 7.5 mg/kg 
bd 
Ami  7.5 mg/kg* No difference 
between standard 
dosing and TDM 
1/41 
(2.4) 
3/41 
(7.3) 
NR NR NR NR NR NR NR NR Trough 4-8 
Peak 25-30 
**Giamarrelou2 60 15 
mg/kg/day* 
Ami  7.5 mg/kg 
bd* 
29/30 
(96.7) 
23/30 
(76.7) 
2/30 
(6.7) 
 
2/30 
(6.7) 
1/30 
(6.7) 
1/30  
(6.7) 
NR NR NR NR NR NR Trough <5 
Peak >40 
**Ibrahim4,5,6, 40 14 mg/kg 
od 
Ami 7 mg/kg bd 20/20 
(100) 
20/20 
(100) 
0/20 0/20 3/20 
(15.0) 
4/20 
(10.0) 
NR NR NR NR 7  7  Measured 
Peak od (49-7-53.1) 
Peak bd (23.5-25.3) 
Maller7,8,9,10 316 15 
mg/kg/day* 
Ami 7.5 mg/kg 
bd* 
92/101 
(91.1) 
89/99 
(89.9) 
9/162 
(5.6) 
11/149 
(7.4) 
3/164 
(1.8) 
2/152  
(1.3) 
1/164 
(0.6) 
1/152 
(0.7) 
8/152 
(5.3) 
7/164 
(4.3) 
5.4  5.9  Trough od <5 
Trough bd <10 
Gilbert27 30 9 mg/kg/day Gent 3-4 
mg/kg/day 
NR NR 2/15 
(13.3) 
2/15 
(13.3) 
0/15 0/15 0/15 0/15 NR NR NR NR Measured 
Peak: 8.2-
19.6 
Peak 4-8 
Holm20  135 7.5 mg/kg 
bd 
Gent 1 mg/kg tds 57/71 
(80.3) 
49/64 
(76.6) 
3/49 
(6.1) 
9/46 
(20.0) 
3/38 
(7.9) 
5/31 
(16.1) 
1/38 
(2.6) 
1/31 
(3.2) 
NR NR NR NR Trough <10  
Peak <35 
Trough < 2 
Peak < 10 
Lerner21 106 6 mg/kg tds* Gent 1.7 mg/kg 
tds* 
NR NR 0/52 8/54 
(14.8) 
7/52 
(13.4) 
6/54 
(11.1) 
NR NR NR NR  ?EŽƐŝŐŶŝĨŝĐĂŶƚ
ĚŝĨĨĞƌĞŶĐĞ ? 
Trough <10 
Peak 15-30 
Trough < 2.5 
Peak 4-8 
Smith11 71 8 mg/kg 
loading* 
Gent 2 mg/kg 
loading* 
20/39 
(51.3) 
14/32 
(43.8) 
5/62 
(8.0) 
7/62 
(11.3) 
2/34 
(5.9) 
3/30 
(10.0) 
NR NR 13/39 
(33.3) 
6/32 
(18.8) 
 ?EŽƐŝŐŶŝĨŝĐĂŶƚ
ĚŝĨĨĞƌĞŶĐĞ ? 
Peak 20-40 Peak 5-10 
Barza23  90 5 mg/kg 8 
hrly* 
Net 2-2.5 mg/kg 
8 hrly* 
Data combined 0/32 3/37 
(8.1) 
4/15 
(26.7) 
3/19 
(15.8) 
3/16 
(18.8) 
0/15 
 
NR NR NR NR Peak 15-25 Peak 6-9 
Bock24 71 7.5 mg/kg 
bd* 
Net 2-2.5 mg/kg 
tds* 
14/33 
(42.4) 
17/34 
(50.0) 
1/29 
(3.4) 
6/34 
(17.6) 
6/23 
(26.1) 
1/29 
(3.4) 
0/29 1/34 
(2.9) 
9/35 
(25.7) 
6/36 
(16.7) 
11.5  11.7  Trough < 5  
Peak <15-25 
dƌŽƵŐŚA䜀  ? 
Peak 4-8 
Maigaard28 57 7.5 mg/kg 
bd 
Net 2 mg/kg bd 16/28 
(57.1) 
20/29 
(70.0) 
No changes in renal 
function 
0/28 0/29 NR NR NR NR NR NR Measured: 
Trough 1.4- 
10.5 
Peak 14- 81 
Trough 0.1-9.2 
Peak 2.6-19.0 
Noone25 202 7.5mg/kg 
bd* 
Net 3.5 mg/kg 
bd* 
74/82 
(90.2) 
68/86 
(79.0) 
4/96 
(4.2) 
11/91 
(12.1) 
7/53 
(13.2) 
8/51 
(15.7) 
NR NR NR NR 10.4  8.5  Trough < 10 
Peak 20-30 
Trough < 4 
Peak 10-15 
Gattell14,15,16 113 7.5 mg/kg 
12-24 hrs* 
Tob 1.7 mg/kg 8-
24 hrs* 
NR NR 7/54 
(13.0) 
4/59 
(6.8) 
6/17 
(35.3) 
8/19 
(42.1) 
NR NR 4/54 
(7.4) 
2/59 
(3.4) 
8.5  8.3  Trough 10 
Peak 40 
Trough 2 
Peak 10 
Chen26 37 500 mg od* Cef 1g qds 11/18 
(61.1) 
15/19 
(78.9) 
1/18 
(5.6) 
1/19 
(5.3) 
NR NR NR NR 4/19 
(21.1) 
4/18 
(22.2) 
NR NR Trough < 30  
Footnote: 485 
Galvez et al20 ƌĞƉŽƌƚĞĚ ?ŶŽĞǀŝĚĞŶĐĞŽĨƌĞŶĂůĨƵŶĐƚŝŽŶŝŵƉĂŝƌŵĞŶƚĂƚĚĂǇ ? ? ?ŽŶ ? ? ?ƉĂƌƚŝĐŝƉĂŶƚƐ given amikacin doses of 15, 20 or 30 mg/kg/day. Dillon et al19 reported no difference in length of hospital stay; 486 
Chen.28 reported 13 days stay for amikacin and 12 for cefotaxime 487 
Key: data are presented as number/total number (percentage), Ami = amikacin, Gent = gentamicin, Net= netilmicin, Tob= tobramycin, Cef = cefotaxime, comp= comparator, od= once daily, bd= twice daily, tds= 488 
three times a day, qds four times daily, hrly= hourly, NR = not reported *Applied therapeutic drug monitoring and dose modification, **includes non-bacteraemic patients489 
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Figure 1 491 
Forest Plot: Nephrotoxicity with Amikacin Versus other 492 
Aminoglycosides4,11,14,20,21,23,24,25 493 
 494 
 495 
Figure 2 496 
Forest Plot: Auditory toxicity of Amikacin Versus other 497 
Aminoglycosides11,14,20,21,23,24,25,27,28 498 
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